Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Central Pacific Bank Trust Division

Central Pacific Bank Trust Division boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 15,158 shares of the biopharmaceutical company’s stock after buying an additional 894 shares during the quarter. Central Pacific Bank Trust Division’s holdings in Gilead Sciences were worth $1,400,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in GILD. State Street Corp increased its position in shares of Gilead Sciences by 1.4% during the 3rd quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company’s stock worth $5,044,795,000 after purchasing an additional 841,776 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Gilead Sciences by 50.9% during the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock valued at $2,900,921,000 after acquiring an additional 11,665,593 shares during the last quarter. FMR LLC raised its stake in shares of Gilead Sciences by 79.4% in the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock valued at $2,780,329,000 after acquiring an additional 14,680,161 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Gilead Sciences by 2.1% in the 3rd quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company’s stock worth $2,302,119,000 after acquiring an additional 574,421 shares during the last quarter. Finally, Legal & General Group Plc boosted its position in shares of Gilead Sciences by 0.8% during the 2nd quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock worth $851,743,000 after purchasing an additional 93,068 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on GILD. Barclays upped their price target on Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 7th. Mizuho raised their target price on Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. The Goldman Sachs Group boosted their price target on shares of Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. Daiwa America raised shares of Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Finally, Maxim Group downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Twelve investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $96.43.

Insider Activity

In related news, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the transaction, the insider now directly owns 99,599 shares in the company, valued at $9,113,308.50. This trade represents a 20.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 8,500 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $91.96, for a total transaction of $781,660.00. Following the completion of the transaction, the chief financial officer now directly owns 132,373 shares in the company, valued at $12,173,021.08. This represents a 6.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 453,734 shares of company stock valued at $41,902,086. Insiders own 0.29% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD traded down $0.04 during midday trading on Friday, reaching $91.84. 1,698,665 shares of the stock were exchanged, compared to its average volume of 2,574,528. The company has a market capitalization of $114.46 billion, a price-to-earnings ratio of 1,020.44, a PEG ratio of 2.38 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90. The business’s 50-day moving average price is $91.76 and its 200 day moving average price is $82.22.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.29 earnings per share. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 4.35 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were paid a $0.77 dividend. The ex-dividend date was Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.35%. Gilead Sciences’s dividend payout ratio is presently 3,422.22%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.